Technology
Health
Biotechnology
Denali Therapeutics
$20.729876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$20.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.04 (0.19%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell DNLI and other stocks, options, ETFs, and crypto commission-free!
About
Denali Therapeutics Inc. Common Stock, also called Denali Therapeutics, is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Read More Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Employees
179
Headquarters
San Francisco, California
Founded
2013
Market Cap
1.97B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
442.03K
High Today
$21.06
Low Today
$20.12
Open Price
$20.41
Volume
212.85K
52 Week High
$28.87
52 Week Low
$12.32
Collections
Technology
Health
Biotechnology
Therapy
Biopharmaceutical
Pharmaceutical
2017 IPO
US
News
Yahoo FinanceMay 8
Denali Therapeutics Reports First Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2019. First Quarter 2019 Financial Results For the three months ended March 31, 2019, Denali reported a net loss of $39.0 million compared with a net loss of $23.7 million for the three months ended March 31, 2018. Collaboration r...
NasdaqMay 8
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Lags Revenue Estimates
Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -10.81%. A quarter ago, it was expected that this company would post a loss of $0.02 per share when it actually produced earnings of $0.79, delivering a surprise of 4,050%. Over the last four quarters, the comp...
Yahoo FinanceApr 30
Here’s What Hedge Funds Think About Denali Therapeutics Inc. (DNLI)
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of December 31. The results of that effort will be put on display in this article, as we share valuable insight into the smart money sentiment towards Denali Therapeutics Inc.
Price Paid on Robinhood
7% Higher
Right Now
52 Week Low
$12.32
Average Price Paid
$19.31
52 Week High
$28.87
Earnings
-$0.59
-$0.13
$0.33
$0.79
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.40 per share
Actual
-$0.41 per share